Search
Semaglutide Treatment Options for Type 2 Diabetes
A collection of 93 research studies in Type 2 Diabetes where Semaglutide is the interventional treatment. Semaglutide is used for conditions such as Type 2 Diabetes.
49 - 60 of 93
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Type 2 Diabetes
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Type 2 Diabetes Clinical Trial
Recruiting
Can changing your breakfast improve your type 2 diabetes? If you have an HbA1C of 7.0% or higher, you are invited to participate in an online study at the University of Michigan.
Conditions:
Type 2 Diabetes
Diabetes Mellitus Type 2 in Obese
Diabetes Type Two
Type 2 Diabetes Mellitus
Diabete Type 2
Featured Trial
Studying an Investigational Monitoring System in Adults with Type 2 Diabetes
Recruiting
The main objectives of this study are to assess the safety and effectiveness of an investigational continuous glucose monitoring system compared to routine care in adults with type 2 diabetes. Additionally, the study aims to evaluate the quality of life improvements that may come with using the investigational device. Should you express interest, you will be contacted directly by the research site, who will provide further details and answer any questions you may have about study requirements, risks/benefits, and any compensation.
Conditions:
All Conditions
Type 2 Diabetes (T2DM)
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease
Recruiting
The purpose of this study is to understand the role of GLP-1 in the pathogenesis of T2D in youth and explore their potential salutary effects and ability to delay the progressive loss of ß-cell function and reduce hepatic steatosis in youth with prediabetes/new onset T2D and NAFLD.
Gender:
ALL
Ages:
Between 10 years and 21 years
Trial Updated:
07/25/2024
Locations: Pediatric Diabetes Center, New Haven, Connecticut
Conditions: Type 2 Diabetes Mellitus, Impaired Glucose Tolerance, Non-Alcoholic Fatty Liver Disease, Obesity, Childhood
Obesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment
Recruiting
More than 40% of young adults with type 1 diabetes (T1D) also have overweight or obesity. Each of these diagnoses increase the risk of adverse cardiovascular events. GLP-1 analogues are anti-obesity medications that are cardioprotective in adults with type 2 diabetes, however evaluation of these agents in people with T1D has been limited to glycemic outcomes. Investigators aim to study the impact of GLP-1 analogue obesity treatment on markers of cardiometabolic risk in young adults with T1D and... Read More
Gender:
ALL
Ages:
Between 18 years and 30 years
Trial Updated:
07/19/2024
Locations: Yale Pediatric Diabetes Center, Adult and Children's Progam, New Haven, Connecticut
Conditions: Diabetes type1, Obesity
Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With Obesity
Terminated
The purpose of this study is to find out if PF-07081532 ("the active study drug"), is safe and helps treat people with obesity without diabetes to lose weight, and people with diabetes to keep their blood sugar in good control. Individuals diagnosed with diabetes that are on metformin or individuals with obesity without diabetes will be included in the study.
Those participating in the diabetes part of the study, will receive either active study drug, placebo, or an approved treatment called Ry... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/09/2024
Locations: Trinity Clinical Research, Centreville, Alabama +89 locations
Conditions: Diabetes Mellitus, Obesity
Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes
Completed
This study looks at how well a new medicine called cagrilintide works together with semaglutide on blood sugar levels in people with type 2 diabetes compared to cagrilintide alone or semaglutide alone.
Before a new medicine can be prescribed to people it needs to be tested to see if it is safe and effective.
Participants will either get cagrilintide and semaglutide together or cagrilintide and a dummy medicine or semaglutide and a dummy medicine. Which treatment participants get is decided by... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/28/2024
Locations: Uni of Alabama at Birmingham, Birmingham, Alabama +17 locations
Conditions: Diabetes Mellitus, Type 2
Pharmacogenetics of Response to GLP1R Agonists
Recruiting
Overweight/obese otherwise healthy volunteers will be recruited from the Old Order Amish population in Lancaster County, PA. Lancaster County, PA. Pharmacodynamic responses to GLP1R agonist will be assessed by conducting frequently sampled intravenous glucose tolerance tests (FSIGT) both before and after semaglutide for six weeks. The proposal proposes two specific aims:
1. Specific Aim #1. To identify genetic variants associated with effects of a GLP1R agonist to enhance glucose-stimulated fir... Read More
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
06/20/2024
Locations: Amish Research Clinic, Lancaster, Pennsylvania
Conditions: Obesity, Diabetes Type 2
GLP-1Ra Impact on Metabolic Outcomes in Stage 2 T1DM While Receiving Teplizumab
Recruiting
The goal of this study is to determine how a drug class called glucagon-like peptide-1 receptor agonists (GLP-1Ra) affects people during an early stage of Type 1 Diabetes undergoing clinical teplizumab treatment. This study involves giving participants a liquid meal under three different conditions and observing how their bodies respond, focusing on blood sugar levels, insulin effectiveness, and blood vessel function. The first meal test is pre-teplizumab, followed by two post-treatment tests, o... Read More
Gender:
ALL
Ages:
Between 12 years and 50 years
Trial Updated:
06/18/2024
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Type 1 Diabetes
Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial
Completed
The main purpose of this study is to compare the effects of semaglutide (Ozempic®) with the effects of other treatments for type 2 diabetes in a normal practice setting. The participant will be assigned by chance (like flipping a coin) to one of the following treatment groups: Group 1: semaglutide (Ozempic®) (by injection into skin) Group 2: standard of care antidiabetic medication (oral or injectable). The participant has an equal chance of being in either of the treatment groups. Neither the p... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/07/2024
Locations: American Clinical Trials, Buena Park, California +121 locations
Conditions: Diabetes Mellitus, Type 2
Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes
Recruiting
The primary objective of this study is to determine the effects of semaglutide on kidney oxygenation and function in type 1 diabetes. The secondary objective is to determine the glycemic effects and safety of semaglutide in type 1 diabetes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2024
Locations: University of Colorado Anschutz Medical Campus, Aurora, Colorado +3 locations
Conditions: Diabetic Kidney Disease, Type 1 Diabetes
Effects of Semaglutide on Intracranial Blood Flow and Brain-Barrier Permeability in Type-2 Diabetes
Recruiting
A human subjects research study, the primary purpose of which is to assess the EFFECTS OF SEMAGLUTIDE ON INTRACRANIAL BLOOD FLOW AND BLOOD-BRAIN BARRIER PERMEABILITY IN TYPE-2 DIABETES (T2D) through testing of the intervention on patients in a clinical setting. The study will randomize subjects with diabetes to either semaglutide or matching placebo. Magnetic resonance images will be primary endpoint measured at baseline and at one year to assess effect of this FDA approved medication.
Given th... Read More
Gender:
ALL
Ages:
Between 40 years and 65 years
Trial Updated:
06/04/2024
Locations: University of Washington - Harborview Medical Center, Seattle, Washington
Conditions: Diabetes Mellitus, Type 2, Stroke (CVA) or Transient Ischemic Attack
Impact of Semaglutide on CD34+ EPC and Fat Derived MSC
Completed
The Investigator is trying to ascertain whether an FDA approved medication of T2DM, Semaglutide, can improve the number, function and gene expression of subjects CD34+ endothelial progenitor cells. EPCs are the source of cells protecting the inner lining of blood vessels and improving their survivability will improve cardiovascular outcome as high glucose environment of diabetes are toxic to these EPC Cells.
Improve mitochondrial metabolism of Mesenchymal Stem Cell from subcutaneous fatty tissu... Read More
Gender:
ALL
Ages:
Between 20 years and 90 years
Trial Updated:
04/24/2024
Locations: The GW Medical Faculty Associates, Washington, District of Columbia +1 locations
Conditions: Diabetes Mellitus, Type 2
GLUCOSE-MGH: Genetic Links Understood Through Challenge With Oral Semaglutide Exposure at MGH
Recruiting
The goal of this research study is to evaluate the pathophysiologic mechanisms by which genetic variation impacts response to an FDA-approved medication commonly used to treat type 2 diabetes called oral semaglutide (Rybelsus) and to characterize the physiological response to a mixed meal tolerance test (MMTT) before and after a 14-day treatment with oral semaglutide. The investigators will do this by measuring factors in the blood, such as sugars, fats, metabolites, and proteins, after eating a... Read More
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
04/15/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Genetic Predisposition, Metabolic Diseases, Type 2 Diabetes
Research Study to Compare Semaglutide Tablets With Empagliflozin or Metformin Tablets in People With Type 2 Diabetes
Withdrawn
This study compares the medicines semaglutide with empagliflozin or metformin in people with newly diagnosed type 2 diabetes. This study will look mainly at how well participant's blood sugar and body weight are controlled when they are taking the study medicines. Participants will either get semaglutide tablets, empagliflozin tablets or metformin tablets. Which treatment participants will get is decided by chance. Currently, doses of 3 milligram (mg), 7 mg and 14 mg semaglutide tablets (Rybelsu... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
02/23/2024
Locations: Hillcrest Family Health Center, Waco, Texas +100 locations
Conditions: Diabetes Mellitus, Type 2
49 - 60 of 93